Date: July 19, 2017
Time: 11:00AM - 1:00PM
The pharma and biotechnology industries have been affected by the recent uptick in patent rejections by the US Patent and Trademark Office (USPTO). Following the release of memorandum on Preliminary Examination Instructions in light of Alice Corp v. CLS Bank in 2014, the USPTO has been stricter in granting patent eligibility under §101. The office has begun issuing Alice rejections — including for pharma and biotech-related patents — where no previous §101 patent eligibility rejection stood. Because of the continued impact of the rejections, it is important to know how pharma and biotechnology industries should gear up for patent protection.
Organized by the Knowledge Group, this webcast will feature a panel of distinguished professionals and thought leaders who will help pharma and biotech professionals understand the important aspects of this significant topic. They will lead an in-depth discussion of patent protection for pharma and biotechnology in 2017. The panelists will also offer best practices for developing and implementing a strategic guide for the pharma and biotech industries to overcome possible rejections.
Topics to be discussed include: